Background illustration for clinical trials search

Paid Clinical Trials Concord

Discover 272 paid clinical trials in Concord, New Hampshire. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 272

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

for

Lichen Planopilaris

Location: Lebanon NH, Burlington MA, Boston MA, Farmington CT,

Sponsor: Priovant Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07532603

Phase2, Phase3, Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

for

Pyoderma Gangrenosum

Location: Lebanon NH, Boston MA, Montreal, Lake Success NY,

Sponsor: LEO Pharma

Sex: All

Age: 18+

Code: NCT06624670

Phase3, Recruiting

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

for

Rectal Cancer

Location: Lebanon NH, Burlington MA, Beverly MA, Gloucester MA,

Sponsor: Canadian Cancer Trials Group

Sex: All

Age: 18+

Code: NCT06205485

Phase3, Recruiting

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for

Myelodysplastic Syndrome

Location: Lebanon NH, Boston MA, Stony Brook NY, Livingston NJ,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase2, Recruiting

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

for

Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma,

Location: Lebanon NH, Boston MA, Scarborough ME, Providence RI,

Sponsor: Children's Oncology Group

Sex: All

Age: 3 - 29

Code: NCT06368817

Phase2, Recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

for

Stage I Mixed Cell Type Kidney Wilms Tumor,

Location: Lebanon NH, Boston MA, Worcester MA, Scarborough ME,

Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 30

Code: NCT06401330

Phase3, Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for

Advanced Melanoma

Location: Lebanon NH, Providence RI, Burlington VT, The Bronx NY,

Sponsor: Replimune, Inc.

Sex: All

Age: 12+

Code: NCT06264180

Phase3, Recruiting

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

for

Angioimmunoblastic T-cell Lymphoma,

Location: Lebanon NH, Boston MA, Saint Johnsbury VT, Harrison NY,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT04803201

Phase2, Recruiting

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Lebanon NH, Boston MA, Scarborough ME,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06672146

Phase2, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Lebanon NH, Boston MA, Harrison NY, Commack NY,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT07097142

Phase3, Recruiting

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

for

Advanced Hepatocellular Carcinoma,

Location: Lebanon NH, Boston MA, Hartford CT, Glastonbury CT,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT07166406

Phase3, Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

for

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Lebanon NH, Brewer ME, Stony Brook NY, Jersey City NJ,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07195734

Phase2, Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for

Locally Advanced Urothelial Carcinoma,

Location: Lebanon NH, Worcester MA, Berlin Corners VT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06524544

Phase3, Recruiting

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for

Buccal Mucosa Squamous Cell Carcinoma,

Location: Lebanon NH, Berlin Corners VT, Burlington VT,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT04333537

Phase2, Phase3, Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for

Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular,

Location: Lebanon NH, Boston MA, Scarborough ME, Providence RI,

Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT03126916

Phase3, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Lebanon NH, Boston MA, Worcester MA, Saint Johnsbury VT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for

Prostate Cancer (Adenocarcinoma)

Location: Lebanon NH, Saint Johnsbury VT, Providence RI,

Sponsor: Canadian Cancer Trials Group

Sex: Male

Age: 18+

Code: NCT06592924

Phase3, Recruiting

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for

Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia

Location: Lebanon NH, Scarborough ME, Providence RI, Hartford CT,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 30

Code: NCT04546399

Phase2, Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

for

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8,

Location: Lebanon NH, Boston MA, Saint Johnsbury VT, The Bronx NY,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06532279

Phase2, Recruiting

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for

B Acute Lymphoblastic Leukemia

Location: Lebanon NH, Boston MA, Worcester MA, Scarborough ME,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 1 - 46

Code: NCT06124157

Phase2, Recruiting

Paid Clinical Trials Concord

Filter results

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Interested in new trials?

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)